Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition (Q36800953)

16 August 2017

1 reference

title

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition (English)

1 reference

16 August 2017

Thomas Force

1 reference

16 August 2017

Daniela S Krause

series ordinal

1 reference

16 August 2017

Richard A Van Etten

series ordinal

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

16 August 2017

published in

Nature Reviews Cancer

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

332-344

1 reference

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

16 August 2017

cites work

1 reference

Chronic health conditions in adult survivors of childhood cancer

31 March 2020

1 reference

Tyrosine kinases as targets for cancer therapy

31 March 2020

1 reference

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

31 March 2020

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

31 March 2020

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

31 March 2020

1 reference

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

31 March 2020

1 reference

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

31 March 2020

1 reference

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

31 March 2020

1 reference

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

31 March 2020

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

BNP as a marker of the heart failure in the treatment of imatinib mesylate

31 March 2020

1 reference

A small molecule-kinase interaction map for clinical kinase inhibitors

31 March 2020

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

31 March 2020

1 reference

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

31 March 2020

1 reference

Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.

31 March 2020

1 reference

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

31 March 2020

1 reference

Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study

31 March 2020

1 reference

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

31 March 2020

1 reference

Clinical cardiac tolerability of trastuzumab

31 March 2020

1 reference

Pathogenesis of cardiotoxicity induced by anthracyclines

31 March 2020

1 reference

Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes

31 March 2020

1 reference

Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes

31 March 2020

1 reference

Requirement for neuregulin receptor erbB2 in neural and cardiac development

31 March 2020

1 reference

Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor

31 March 2020

1 reference

Multiple essential functions of neuregulin in development

31 March 2020

1 reference

ErbB2 is essential in the prevention of dilated cardiomyopathy.

31 March 2020

1 reference

Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

31 March 2020

1 reference

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

31 March 2020

1 reference

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

31 March 2020

1 reference

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

31 March 2020

1 reference

Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression

31 March 2020

1 reference

Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy

31 March 2020

1 reference

Reduced Apaf-1 levels in cardiomyocytes engage strict regulation of apoptosis by endogenous XIAP.

31 March 2020

1 reference

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

31 March 2020

1 reference

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

31 March 2020

1 reference

31 March 2020

1 reference

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

31 March 2020

1 reference

How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.

31 March 2020

1 reference

Adverse event reporting in publications compared with sponsor database for cancer clinical trials

31 March 2020

1 reference

AMPK alterations in cardiac physiology and pathology: enemy or ally?

31 March 2020

1 reference

Glutamate-induced neuronal death: A succession of necrosis or apoptosis depending on mitochondrial function

31 March 2020

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

31 March 2020

1 reference

Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C delta

31 March 2020

1 reference

Glutathione peroxidase 1 is regulated by the c-Abl and Arg tyrosine kinases

31 March 2020

1 reference

Catalase activity is regulated by c-Abl and Arg in the oxidative stress response

31 March 2020

1 reference

Ubiquitination and degradation of the Arg tyrosine kinase is regulated by oxidative stress

31 March 2020

1 reference

The unfolded protein response: a stress signaling pathway critical for health and disease.

31 March 2020

1 reference

Signaling the unfolded protein response from the endoplasmic reticulum.

31 March 2020

1 reference

Translational control in the endoplasmic reticulum stress response

31 March 2020

1 reference

Distinctive activation mechanisms and functions for protein kinase Cdelta

31 March 2020

1 reference

Targeting of the c-Abl tyrosine kinase to mitochondria in endoplasmic reticulum stress-induced apoptosis

31 March 2020

1 reference

Interaction between protein kinase C delta and the c-Abl tyrosine kinase in the cellular response to oxidative stress

31 March 2020

1 reference

Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr-abl tyrosine kinase

31 March 2020

1 reference

Reversal of experimental pulmonary hypertension by PDGF inhibition

31 March 2020

1 reference

Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis.

31 March 2020

1 reference

Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylate

31 March 2020

1 reference

Multi-kinase inhibitors create buzz at ASCO.

31 March 2020

1 reference

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

31 March 2020

1 reference

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

31 March 2020

1 reference

Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity

31 March 2020

1 reference

AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress

31 March 2020

1 reference

Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism

31 March 2020

1 reference

Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1.

31 March 2020

1 reference

Role of raf proteins in cardiac hypertrophy and cardiomyocyte survival

31 March 2020

1 reference

Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling

31 March 2020

1 reference

Taming the Hippo: Raf-1 controls apoptosis by suppressing MST2/Hippo

31 March 2020

1 reference

Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis

31 March 2020

1 reference

Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload

31 March 2020

1 reference

Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure

31 March 2020

1 reference

Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload

31 March 2020

1 reference

p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload

31 March 2020

1 reference

Restoration of p53 function leads to tumour regression in vivo

31 March 2020

1 reference

Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction

31 March 2020

1 reference

STAT3-mediated activation of myocardial capillary growth

31 March 2020

1 reference

Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury

31 March 2020

1 reference

Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy

31 March 2020

1 reference

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

31 March 2020

1 reference

Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction.

31 March 2020

1 reference

Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines

31 March 2020

1 reference

Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?

31 March 2020

1 reference

Focus on myeloproliferative diseases and myelodysplastic syndromes

31 March 2020

1 reference

31 March 2020

Focus on acute leukemias

1 reference

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

31 March 2020

1 reference

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

31 March 2020

1 reference

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

31 March 2020

1 reference

The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1

31 March 2020

1 reference

Mechanisms of cutaneous toxicities to EGFR inhibitors.

31 March 2020

1 reference

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro

31 March 2020

1 reference

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo

31 March 2020

1 reference

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

31 March 2020

1 reference

Requirement for Abl kinases in T cell receptor signaling

31 March 2020

1 reference

Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia

31 March 2020

1 reference

Imatinib inhibits the functional capacity of cultured human monocytes.

31 March 2020

1 reference

The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation

31 March 2020

1 reference

Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance

31 March 2020

1 reference

Caspases: pharmacological manipulation of cell death

31 March 2020

1 reference

Apoptosis-based therapies

31 March 2020

1 reference

Death begets failure in the heart

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC2106

1 reference

Dimensions Publication ID

16 August 2017

1042110823

0 references

1 reference